Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820194 | 1.00 | TAAR1 (0.59) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL10302995 | 1.00 | TAAR1 (0.59) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL1130128 | 1.00 | TAAR1 (0.59) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL23393910 | 0.87 | TAAR1 (0.47) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL23054771 | 0.87 | TAAR1 (0.47) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL21444969 | 0.86 | TAAR1 (0.46) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4587339 | 0.85 | TAAR1 (0.56) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4416002 | 0.85 | TAAR1 (0.56) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL13788689 | 0.85 | TAAR1 (0.56) | TAAR1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4586186 | 0.85 | TAAR1 (0.56) | TAAR1MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354802-A | Preparation method of chiral benzyl secondary alcohol compound | 上海毕得医药科技股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-111548329-B | Preparation method of brivaracetam | 浙江乐普药业股份有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-111548329-A | Preparation method of brivaracetam | 浙江乐普药业股份有限公司 | 2020-08-18 | — | — | CN | claimed |
| CN-116354802-A | Preparation method of chiral benzyl secondary alcohol compound | 上海毕得医药科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-111548329-B | Preparation method of brivaracetam | 浙江乐普药业股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3896058-A2 | ENANTIONSELECTIVE PROCESSES TO INSECTICIDAL 3-ARYL-3-TRIFLUOROMETHYL-SUBSTITUTED PYRROLIDINES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| EP-2763963-B1 | ENANTIONSELECTIVE PROCESSES TO INSECTICIDAL 3-ARYL-3-TRIFLUOROMETHYL-SUBSTITUTED PYRROLIDINES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-111548329-A | Preparation method of brivaracetam | 浙江乐普药业股份有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-9469633-B2 | Processes for the preparation of pyrrolidine intermediates | SYNGENTA PARTICIPATIONS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-9469633-B2 | Processes for the preparation of pyrrolidine intermediates | SYNGENTA PARTICIPATIONS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2014-11-27 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1253135-B1 | Asymmetric copper complex and cyclopropanation reaction using the same | SUMITOMO CHEMICAL CO (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100056806-A1 | C-H Bond Amination and Olefin Aziridination with Beta-Diketiminato Copper Catalysts | GEORGETOWN UNIVERSITY (US) | 2010-03-04 | — | — | US | disclosed |
| US-6858559-B2 | Using copper complex containing oxazole molecules | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20020177718-A1 | Asymmetric copper complex and cyclopropanation reaction using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1253135-A1 | Asymmetric copper complex and cyclopropanation reaction using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123645-A1 | Method for producing optically active chrysanthemic acid | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-09-05 | — | — | US | disclosed |
| EP-1236708-A1 | Method for producing optically active chrysanthemic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123645-A1 | Method for producing optically active chrysanthemic acid | ENO1, CYP8B1, CRYAA | TAAR1 4555/4885MAPT 1433/4885ALDH1A1 1283/4885 |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | TAAR1 795/4885MAPT 3525/4885ALDH1A1 1717/4885 |
| US-20100056806-A1 | C-H Bond Amination and Olefin Aziridination with Beta-Diketiminato Copper Catalysts | AOC2, AOC1, AOC3 | TAAR1 1993/4885MAPT 4498/4885ALDH1A1 20/4885 |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | TAAR1 4350/4885MAPT 4735/4885ALDH1A1 357/4885 |
| US-20020177718-A1 | Asymmetric copper complex and cyclopropanation reaction using the same | AOC3, AOC1, ACSL3 | TAAR1 1431/4885MAPT 4820/4885ALDH1A1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.